Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis

• Published in: Investigational new drugs 2024-10, Vol.42 (5), p.510-517
• Main Authors: Wu, Zhaoquan, Sun, Wei, Wang, Chunjiang
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Cancer therapies; Case reports; Child; Disease; Drug withdrawal; Drugs; Female; Health services; Humans; Immunotherapy; Kidney cancer; Lung cancer; Male; Medical history; Medical treatment; Medicine; Medicine & Public Health; Melanoma; Middle Aged; Oncology; Patients; Pembrolizumab; Pharmacology/Toxicology; Pharmacy; R&D; Research & development; Retrospective Studies; Signs and symptoms; Steroid hormones; Steroids; Treatment Outcome; Tumors; Uveitis; Uveitis - chemically induced; Uveitis - drug therapy; Vision; Visual acuity; Young Adult
• ISSN: 0167-6997; 1573-0646; 1573-0646
• DOI: 10.1007/s10637-024-01464-w

Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The aim of this study was to investigate the clinical characteristics of pembrolizumab-induced uveitis and to provide reference for prevention, diagnosis and treatment. We collected studies related to pembrolizumab-induced uveitis by searching databases for retrospective analysis until April 30, 2024. The median age of the 31 patients was 63 years (range 7, 82), and the median duration of uveitis onset was 12 weeks (range 0.4, 108). Decreased vision (41.9%) and blurred vision (25.8%) were the most common complaints. Uveitis can be manifested as Vogt-Koyanagi-Harada disease-like uveitis (22.6%) and Birdshot uveitis (6.5%). Uveitis mainly affects both eyes and is related to anterior uveitis (35.5%), panuveitis (25.8%) and posterior uveitis (19.4%). Patients receiving topical steroid drops, systemic steroids, and withdrawal of pembrolizumab significantly improved symptoms at a median time of 4 weeks (range 2, 16). The possibility of uveitis should be considered when patients are treated with pembrolizumab and experience eye symptoms such as blurred vision and decreased vision. Depending on the severity of uveitis, treatment with topical and systemic steroids may be selected.